<!DOCTYPE html>
<html>
    <head>
        <meta charset="utf-8" />
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=1.0, maximum-scale=1.0, minimum-scale=1.0, user-scalable=no" />
        <title>Full STD Tx Guidelines</title>

        <link href="../jquery-mobile/jquery.mobile.theme-1.2.0.min.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.swatch.f.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.swatch.j.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/custom_arrow.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.structure-1.2.0.min.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/full.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/recreated_tables.css" rel="stylesheet" type="text/css"/>
        <script src="../jquery-mobile/jquery-1.8.2.min.js" type="text/javascript"></script>
        <script src="../jquery-customization.js" type="text/javascript"></script>
        <script src="../jquery-mobile/jquery.mobile-1.2.0.min.js" type="text/javascript"></script>
        <script src="../cordova-2.2.0.js" type="text/javascript" charset="utf-8"></script>
        <script src="../assets/js/metrics.js" type="text/javascript" charset="utf-8"></script>

    </head>
    <body>

        <!-- Start of page -->
        <div data-role="page" id="heading_page_416" data-theme="d">
            <div data-role="header" data-id="guidelines-header" data-theme="j" data-position="fixed">
                <a href="lv-409.html" data-role="button" data-iconshadow="false" data-corners="false" data-theme="reset" data-transition="fade" class="back_button" role="button" aria-label="back"></a>
                <h1>Full STD Tx Guidelines</h1>
	            <a href="../menu.html"  rel="external" data-role="button" data-theme="reset" data-transition="fade" data-iconshadow="false" data-corners="false" class="menu_button ui-btn-right" role="button" aria-label="main menu"></a>
            </div>  <!-- end of header div -->

            <div data-role="content">
            <div id=guidelines_breadcrumbs>
            
                    <a href="lv-0.html" >Full Guidelines</a><span class="carrot"> > </span>
                    <a href="lv-409.html" >References</a><span class="carrot"> > </span>References 301-350
            </div>   <!-- end of guidelines listview breadcrumbs -->
            </br><h2 id="sigil_toc_id_416">
 References 301-350
</h2>
<p>
 301. Lo JY, Ho KM, Leung AO, et al. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother 2008;52:3564&ndash;7.
</p>
<p>
 302. Deguchi T, Yasuda M, Yokoi S, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother 2003;9:35&ndash;9.
</p>
<p>
 303. Yokoi S, Deguchi T, Ozawa T, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007;13:1275&ndash;7.
</p>
<p>
 304. Muratani T, Akasaka S, Kobayashi T, et al. Outbreak of cefozopran (penicillin, oral cephems, and aztreonam)-resistant Neisseria gonorrhoeae in Japan. Antimicrob Agents Chemother 2001;45:3603&ndash;6.
</p>
<p>
 305. Wang SA, Lee MV, O&rsquo;Connor N, et al. Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime-Hawaii, 2001. Clin Infect Dis 2003;37:84952.
</p>
<p>
 306. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated&nbsp;gonococcal infections. Clin Infect Dis 1995;20 Suppl 1:S47&ndash;S65.
</p>
<p>
 307. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007;44 Suppl 3:S84&ndash;101.
</p>
<p>
 308. Pandori M, Barry PM, Wu A, et al. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob Agents Chemother 2009;53:4032&ndash;4.
</p>
<p>
 309. Ison CA, Mouton JW, Jones K, et al. Which cephalosporin for gonorrhoea?&nbsp;Sex Transm Infect 2004;80:386&ndash;8.
</p>
<p>
 310. CDC. Notice to Readers: Discontinuation of Spectinomycin. MMWR 2006;55:370.
</p>
<p>
 311. Waters LJ, Boag FC, Betournay R. Efficacy of azithromycin 1 g single dose in the management of uncomplicated gonorrhoea. Int J STD AIDS 2005;16:84.
</p>
<p>
 312. McLean CA, Wang SA, Hoff GL, et al. The emergence of Neisseria gonorrhoeae with decreased susceptibility to azithromycin in Kansas City, Missouri, 1999 to 2000. Sex Transm Dis 2004;31:73&ndash;8.
</p>
<p>
 313. Chisholm SA, Neal TJ, Alawattegama AB, et al. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother 2009;64:353&ndash;8.
</p>
<p>
 314. Linhart Y, Shohat T, Amitai Z, et al. Sexually transmitted infections among brothel-based sex workers in Tel-Aviv area, Israel: high prevalence&nbsp;of pharyngeal gonorrhoea. Int J STD AIDS 2008;19:656&ndash;9.
</p>
<p>
 315. Ota KV, Fisman DN, Tamari IE, et al. Incidence and treatment outcomes&nbsp;of pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis infections in men who have sex with men: a 13-year retrospective cohort study. Clin Infect Dis 2009;48:1237&ndash;43.
</p>
<p>
 316. Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 2005;115:1048&ndash;57.
</p>
<p>
 317. Haimovici R, Roussel TJ. Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftriaxone. Am J Ophthalmol 1989;107:511&ndash;4.
</p>
<p>
 318. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial&nbsp;vaginosis in the United States, 2001&ndash;2004: associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 2007;34:864&ndash;9.
</p>
<p>
 319. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983;74:14&ndash;22.
</p>
<p>
 320. Schwebke JR, Hillier SL, Sobel JD, et al. Validity of the vaginal gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol 1996;88(4 Pt 1):573&ndash;6.
</p>
<p>
 321. Fredricks DN, Fiedler TL, Thomas KK, et al. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol 2007;45:3270&ndash;6.
</p>
<p>
 322. Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol 2007;196:517&ndash;6.
</p>
<p>
 323. Livengood CH, III, Ferris DG, Wiesenfeld HC, et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized&nbsp;controlled trial. Obstet Gynecol 2007;110(2 Pt 1):302&ndash;9.
</p>
<p>
 324. Sobel J, Peipert JF, McGregor JA, et al. Efficacy of clindamycin vaginal ovule (3-day treatment) vs. clindamycin vaginal cream (7-day treatment) in bacterial vaginosis. Infect Dis Obstet Gynecol 2001;9:9&ndash;15.
</p>
<p>
 325. Antonio MA, Meyn LA, Murray PJ, et al. Vaginal colonization by probiotic Lactobacillus crispatus CTV-05 is decreased by sexual activity and endogenous Lactobacilli. J Infect Dis 2009;199:1506&ndash;13.
</p>
<p>
 326. Mastromarino P, Macchia S, Meggiorini L, et al. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic&nbsp;bacterial vaginosis. Clin Microbiol Infect 2009;15:67&ndash;74.
</p>
<p>
 327. Hemmerling A, Harrison W, Schroeder A, et al. Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis. Sex Transm Dis 2009;36:564&ndash;9.
</p>
<p>
 328. Ferris MJ, Masztal A, Aldridge KE, et al. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis 2004;4:5.
</p>
<p>
 329. Bradshaw CS, Tabrizi SN, Fairley CK, et al. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis&nbsp;and recurrence after oral metronidazole therapy. J Infect Dis 2006;194:828&ndash;36.
</p>
<p>
 330. Marrazzo JM, Thomas KK, Fiedler TL, et al. Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med 2008;149:20&ndash;8.
</p>
<p>
 331. Meltzer MC, Desmond RA, Schwebke JR. Association of Mobiluncus curtisii with recurrence of bacterial vaginosis. Sex Transm Dis 2008;35:611&ndash;3.
</p>
<p>
 332. Beigi RH, Austin MN, Meyn LA, et al. Antimicrobial resistance associated&nbsp;with the treatment of bacterial vaginosis. Am J Obstet Gynecol 2004;191:1124&ndash;9.
</p>
<p>
 333. Nyirjesy P, McIntosh MJ, Steinmetz JI, et al. The effects of intravaginal&nbsp;clindamycin and metronidazole therapy on vaginal mobiluncus morphotypes in patients with bacterial vaginosis. Sex Transm Dis 2007;34:197&ndash;202.
</p>
<p>
 334. Bunge KE, Beigi RH, Meyn LA, et al. The efficacy of retreatment with the same medication for early treatment failure of bacterial vaginosis. Sex Transm Dis 2009;36:711&ndash;3.
</p>
<p>
 335. Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006;194:1283&ndash;9.
</p>
<p>
 336. Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis 2009;36:732&ndash;4.
</p>
<p>
 337. Mcclelland RS, Richardson BA, Hassan WM, et al. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis 2008;197:1361&ndash;8.
</p>
<p>
 338. Hauth JC, Goldenberg RL, Andrews WW, et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995;333:1732&ndash;6.
</p>
<p>
 339. Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol 1994;171:345&ndash;7.
</p>
<p>
 340. Yudin MH, Landers DV, Meyn L, et al. Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial&nbsp;vaginosis during pregnancy: a randomized trial. Obstet Gynecol 2003;102:527&ndash;34.
</p>
<p>
 341. Ugwumadu A, Reid F, Hay P, et al. Natural history of bacterial vaginosis and intermediate flora in pregnancy and effect of oral clindamycin. Obstet Gynecol 2004;104:114&ndash;9.
</p>
<p>
 342. Burtin P, Taddio A, Ariburnu O, et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995;172(2 Pt 1):525&ndash;9.
</p>
<p>
 343. Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 1993;82:348&ndash;52.
</p>
<p>
 344. Odendaal HJ, Popov I, Schoeman J, et al. Preterm labour&mdash;is bacterial vaginosis involved? S Afr Med J 2002;92:231&ndash;4.
</p>
<p>
 345. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent&nbsp;preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 2000;342:534&ndash;40.
</p>
<p>
 346. Vermeulen GM, Bruinse HW. Prophylactic administration of clindamycin&nbsp;2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised&nbsp;placebo-controlled double-blind trial. Br J Obstet Gynaecol 1999;106:652&ndash;7.
</p>
<p>
 347. McDonald HM, O&lsquo;Loughlin JA, Vigneswaran R, et al. Impact of metronidazole&nbsp;therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial. Br J Obstet Gynaecol 1997;104:1391&ndash;7.
</p>
<p>
 348. Hay P, Ugwumadu AHN, Manyonda IT. Oral clindamycin prevents spontaneous&nbsp;preterm birth and mid trimester miscarriage in pregnant women with bacterial vaginosis. Int J STD AIDS 2001;12(Suppl 2):70&ndash;1.
</p>
<p>
 349. Lamont RF, Duncan SL, Mandal D, et al. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol 2003;101:516&ndash;22.
</p>
<p>
 350. McGregor JA, French JI, Jones W, et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol 1994;170:1048&ndash;59.
</p>

            </div>
            <script type="text/javascript">

                $('div').live('pageshow', function (event, ui) {
                    document.addEventListener("deviceready", function(){
                        trackFullGuidelinesPageView("416");
                                                },true);
                });
            </script>
        </div>
        <!-- end of guidelines heading page -->
    </body>
</html>

    